A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Prior treatment

• Use of moderate or strong CYP3A4 inhibitors or inducers.
• Have participated within the last 30 days in a clinical trial involving an investigational product.

Other illness

• Have significant central nervous system or psychiatric disease, other than AD, that in the investigator's opinion may affect cognition or the ability to complete the study (e.g: head trauma, stroke, seizure disorder etc.,).
• Have cardiovascular-related risk factors or history that include uncontrolled hypertension, heart failure, stroke; or liver-related abnormalities.

Other

• Are individuals of childbearing potential.
• Participant is, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.

• Have gradual and progressive decline in memory function for greater than or equal to 6 months that is severe enough to interfere with activities of daily living.
• Have MMSE score of 13 to 24.
• Have eligibile plasma P-tau or historical evidence of AD pathology.
• Have a reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant and will be available at designated times.
• Males with partners of childbearing potential must agree to abide with provided contraception guidance.